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stratiﬁ cation to mono- or adjunct therapy. Outcome variables were patient- and physi-
cian-reported treatment SEU ratings at weeks 4 and 12. Predictors included change
from baseline in the bradykinesia subscale of the Uniﬁ ed Parkinson’s Disease Rating
Scale, change from baseline in patient- and physician-reported Activities of Daily 
Living (ADL), and patient- and physician-reported Clinical Global Impression (CGI).
Data were analyzed using linear regression. RESULTS: SEU ratings with rasagiline 
were positive at all visits. Complete data were available for 109 monotherapy and 
131 adjunct therapy patients at week 12. Patient- and physician-reported CGI 
were positively related to SEU ratings reported by the same individual at the same 
visit (p  0.05); patient-reported CGI was positively related to physician-reported SEU
ratings at week 4 (p  0.05). Bradykinesia improvement from baseline predicted physi-
cian-reported SEU ratings at week 4 for monotherapy (p  0.01). Patient-reported
ADL improvement from baseline predicted patient-reported SEU ratings at week 12 
for adjunct therapy (p  0.01). CONCLUSIONS: Patient- and physician-reported CGI 
were consistently related to patient- and physician-reported SEU ratings with rasagi-
line. Furthermore, improvement in bradykinesia symptoms and patient-reported ADL
predicted subsequent ratings of treatment SEU in some cases. Additional research on 
patient- and physician-reported treatment SEU scales in PD populations is needed to 
reﬁ ne this important endpoint.
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OBJECTIVES: Multiple Sclerosis (MS) is an immunomediated, highly disabling
disease affecting young adults. The demographic characteristics, disease modifying 
therapies and health resources utilization by patients followed at a MS reference center
in Sao Paulo, Brazil are presented. METHODS: Patient’s charts were reviewed from 
a retrospective cohort of 353 MS patients. Patients were selected by attendance to 
outpatient visits at Hospital das Clínicas, Faculty of Medicine – University of Sao 
Paulo from March to May 2008. RESULTS: From 353 patients, 74% were female
and 86% were white-Caucasians. A positive family history was identiﬁ ed in ﬁ ve
patients. Sixty-eight percent had relapsing-remitting MS, 13% secondary progressive
MS and 10% primary progressive MS. Half of the patients had MS diagnosis for less 
than 5 years. At the last interview, 226 patients (64%) were on immunomodulatory
agents. From these, 59 patients were using glatiramer acetate and 167 were using 
beta-interferons. The immunomodulatory drug was changed in 11 patients. Sixty-one 
patients (17%) were on immunossupressants, with 31% using azathioprine. Average 
EDSS score at last visit was 4.2. Approximately 24% of patients had at least one 
relapse requiring treatment and 5% were hospitalized in the last 12 months. CON-
CLUSIONS: There are few data on epidemiology and health resource use published 
in Latin-American countries, while many countries like Brazil provide high-cost treat-
ments at public health system. In our study, the current approved MS therapies were
widely used. Therefore, the understanding of local patients’ characteristics and health 
resources use can provide data for an optimized, tailored disease management solu-
tions in these countries.
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OBJECTIVES: Examine the patient characteristics, treatment patterns and cost of care
among Parkinson’s Disease (PD) residents in a long term care (LTC) setting, speciﬁ -
cally, skilled nursing facilities (SNFs) in the US. PD is a progressive neurodegenerative
disorder that produces considerable morbidity. The prevalence and incidence of PD 
increase with age. PD affects more than 3% of individuals over 65 years old.
METHODS: Retrospective analysis of PD patients in SNFs from June 2004–2008.
Using a large provider database, 7885 PD patients were identiﬁ ed. Patient demograph-
ics, comorbidities, treatment patterns and costs were assessed using administrative and 
clinical databases at baseline and one year (1 year). RESULTS: A total of 4150 PD 
patients with baseline and 1 year data constituted the analysis cohort, mean age of 
82 years, 46% male and 57% admitted from an acute care hospital. At baseline, 43%
had fallen in the past 30 days, 94% reported bathing assistance; 24% and 38% were
bladder and bowel continent; 71% and 44% suffered short and long-term memory 
loss. Patients received speech, occupational and physical therapy for 68, 153 and 157
minutes per week. The average patient had 6 comorbid conditions: hypertension
(64%), depression (46%), dementia (43%) and diabetes (31%) were common. 83%
were diagnosed with PD before or at SNF admission. At baseline, 79% were PD 
medication-free; 49% remained PD medication-free over 1y. Patients averaged 11
medications. Concomitant medication use of analgesics, antihypertensives and antide-
pressants were the most common. Direct LTC monthly medical costs were $5355 and
$6097 at baseline and 1 year. CONCLUSIONS: PD patients have physical and cogni-
tive impairment, combined with debilitating comorbidities. Falls, incontinence, 
memory loss, hypertension, depression, dementia and diabetes complicate PD treat-
ment in LTC. Concomitant medication burden further complicates treatment. Ongoing
examination into treatment needs and barriers to PD medication use is needed to
alleviate PD burden in LTC.
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OBJECTIVES: Our study aims to identify socioeconomic factors related to insomnia
prescription patterns in US outpatient settings. METHODS: This project proposes a 
secondary data analysis using a national longitudinal database from 2004 National 
Ambulatory Medical Care Survey (NAMCS). Study subjects were derived from out-
patient visits in which at least one insomnia drug was prescribed. A series of weighted
chi-square statistics were performed to compare insomnia drug uses across various
physician and patient characteristics. All analyses used SAS statistical software and 
incorporated sample weights and standard errors correction. RESULTS: Among the 
910 million outpatient visits that took place in the US in 2004, an estimated 24.
98 million visits included at least one insomnia drug prescription. The majority of 
prescriptions were allocated to antidepressants (52.3%), which were more frequently 
prescribed than non-benzodiazepines (34.1%) and benzodiazepines (13.6%). Differ-
ences in drug pricing may explain these ﬁ ndings: the average wholesale price (AWP) 
for antidepressants is lower ($0.31) than non-benzodiazepine hypnotics ($2.52). 
Patient comparisons by insurance type revealed that Medicaid patients were less likely 
to receive the relatively expensive non-benzodiazepines (27.55%) than Medicare 
(32.53%), self-pay (33.39%), and private insurance (35.03%) patients. Prescribing
patterns were signiﬁ cantly inﬂ uenced by physician specialty (P  0.0001), with general/
family physicians contributing the greatest frequency of insomnia prescriptions 
(36.1%). Females received signiﬁ cantly more insomnia prescriptions than males (16.4
mil. vs. 8.58 mil.; P  0.0001) and Black/Hispanics received signiﬁ cantly fewer
insomnia prescriptions than did white patients (10.78% vs. 87.13%, P  0.0001). 
CONCLUSIONS: Our ﬁ ndings indicate signiﬁ cant socioeconomic disparities in the 
use of insomnia prescriptions. While drug pricing might account for some of our 
results, marketing—particularly the sociodemographic and physician characteristics
toward which such efforts are targeted—provides another strong explanation for
prescription pattern disparities. Further evaluation of current practice guidelines and
development of more manageable regulations might ensure greater consistency in 
treatment patterns.
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OBJECTIVES: To analyse the utilisation of drugs for treatment of neurological disor-
der (ATC group: N01–N07) within Slovakia between 1999 and 2007 and to asses the
economic consequences of the medications. METHODS: For 1999–2007, the data
about consumption of drugs for treatment of neurological disorder were collected 
following ATC/DDD methodology. Data of wholesalers, who are legally obliged
provide this information to the Slovak Institute for Drug Control, was used for
the analysis. The results were expressed in the numbers of the packages, ﬁ nance units 
(€) and deﬁ ned daily doses per 1000 inhabitants per day (DID). RESULTS: The col-
lected data showed a signiﬁ cant increases in consumption of drugs for treatment of 
neurological disorder from 1999 to 2007 in term of DID (in 1999 (108.92), in 2003
(119.46) and in 2007 (142.57). A large increase in consumption of psychoanaleptics
(in 1999 (16.00), in 2003 (33.22) and in 2007 (44.84) and a stable consumption of 
psycholeptics in 1999 (40.88), in 2003 (38.33) and in 2007 (41.34) in term of DID 
can be seen from this analysis. We can see a slight increase in consumption of drugs 
in term of DID within the group of antiepileptics (in 1999 (4.60), in 2003 (5.25) and
in 2007 (6.86) and anti-parkinson drugs (in 1999 (3.19), in 2003 (3.81) and in 2007 
(3.92). Financial expenditures for psychoanaleptics (in 1999 (€16,613,000), in 2003 
(€40,572,000) and in 2007 (€30,382,000), for psycholeptics (in 1999 (€10,504,000), 
in 2003 (€24,603,000) and in 2007 (€36,502,000) can be seen from this study. CON-
CLUSIONS: Inseparable components of the Slovak drug policy must be viewed real-
istically with regard to the consumption of drugs for neurological disorder. Adherence 
to principles of neurological treatment’s guidelines lead to fundamental short and long
term ﬁ nancial savings within health care systems.
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OBJECTIVES: Cholinesterase (ChE) inhibitors, including donepezil and rivastigmine,
are standard of care for mild to moderate cognitive impairment due to Alzheimer’s 
disease (AD). The current study investigates whether treatment with rivastigmine is
associated with less use of antipsychotics compared to treatment with donepezil. 
METHODS: A claims analysis was conducted from 01/2004 through 12/2006 using
the MedStat MarketScan database. Patients included had continuous insurance cover-
age, had at least 1 diagnosis of AD, and were newly initiated on either rivastigmine
or donepezil after the ﬁ rst AD claim. Patients using memantine or receiving antipsy-
chotics in the time interval of q180 days before and 14 days after the ﬁ rst rivastigmine 
or donepezil drug dispensing were excluded. Both Kaplan-Meier and multivariate Cox 
